These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 20179808)

  • 41. Adjuvant endocrine therapy of perimenopausal and recently postmenopausal women with hormone receptor-positive breast cancer.
    Pan K; Chlebowski RT
    Clin Breast Cancer; 2014 Jun; 14(3):147-53. PubMed ID: 24503025
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Safety profiles of tamoxifen and the aromatase inhibitors in adjuvant therapy of hormone-responsive early breast cancer.
    Perez EA
    Ann Oncol; 2007 Sep; 18 Suppl 8():viii26-35. PubMed ID: 17890211
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Hormonal approaches to breast cancer treatment and prevention: an overview.
    Vogel CL
    Semin Oncol; 1996 Aug; 23(4 Suppl 9):2-9. PubMed ID: 8824459
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Estrogen receptor genotypes influence hot flash prevalence and composite score before and after tamoxifen therapy.
    Jin Y; Hayes DF; Li L; Robarge JD; Skaar TC; Philips S; Nguyen A; Schott A; Hayden J; Lemler S; Storniolo AM; Flockhart DA; Stearns V
    J Clin Oncol; 2008 Dec; 26(36):5849-54. PubMed ID: 19018086
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The addition of hormone therapy to tamoxifen does not prevent hot flashes in women at high risk for developing breast cancer.
    Osborne CR; Duncan A; Sedlacek S; Paul D; Holmes F; Vukelja S; Kasper M; Wilks S; Schneider A; McGee R; Meyer WG; O'Shaughnessy JA
    Breast Cancer Res Treat; 2009 Aug; 116(3):521-7. PubMed ID: 19139988
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Hot flash management: update of the evidence for patients with cancer.
    Kaplan M; Mahon S
    Clin J Oncol Nurs; 2014; 18 Suppl():59-67. PubMed ID: 25427609
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pathophysiology and management of hot flashes.
    Dalal S; Zhukovsky DS
    J Support Oncol; 2006; 4(7):315-20, 325. PubMed ID: 16892692
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Managing the toxicities of the aromatase inhibitors.
    Mortimer JE
    Curr Opin Obstet Gynecol; 2010 Feb; 22(1):56-60. PubMed ID: 20019610
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparison of menopausal symptoms during the first year of adjuvant therapy with either exemestane or tamoxifen in early breast cancer: report of a Tamoxifen Exemestane Adjuvant Multicenter trial substudy.
    Jones SE; Cantrell J; Vukelja S; Pippen J; O'Shaughnessy J; Blum JL; Brooks R; Hartung NL; Negron AG; Richards DA; Rivera R; Holmes FA; Chittoor S; Whittaker TL; Bordelon JH; Ketchel SJ; Davis JC; Ilegbodu D; Kochis J; Asmar L
    J Clin Oncol; 2007 Oct; 25(30):4765-71. PubMed ID: 17947724
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Using traditional acupuncture for breast cancer-related hot flashes and night sweats.
    de Valois BA; Young TE; Robinson N; McCourt C; Maher EJ
    J Altern Complement Med; 2010 Oct; 16(10):1047-57. PubMed ID: 20954961
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer.
    Berry J
    Clin Ther; 2005 Nov; 27(11):1671-84. PubMed ID: 16368441
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Overview of long term care of breast cancer survivors.
    Brennan ME; Houssami N
    Maturitas; 2011 Jun; 69(2):106-12. PubMed ID: 21489727
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Progress in tailoring adjuvant endocrine therapy for postmenopausal women with early breast cancer.
    Bedard PL; Piccart-Gebhart MJ
    Curr Opin Oncol; 2009 Nov; 21(6):491-8. PubMed ID: 19593135
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cimicifuga racemosa for the treatment of hot flushes in women surviving breast cancer.
    Hernández Muñoz G; Pluchino S
    Maturitas; 2003 Mar; 44 Suppl 1():S59-65. PubMed ID: 12609560
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Evaluation of soy phytoestrogens for the treatment of hot flashes in breast cancer survivors: A North Central Cancer Treatment Group Trial.
    Quella SK; Loprinzi CL; Barton DL; Knost JA; Sloan JA; LaVasseur BI; Swan D; Krupp KR; Miller KD; Novotny PJ
    J Clin Oncol; 2000 Mar; 18(5):1068-74. PubMed ID: 10694559
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses.
    Baum M; Buzdar A; Cuzick J; Forbes J; Houghton J; Howell A; Sahmoud T;
    Cancer; 2003 Nov; 98(9):1802-10. PubMed ID: 14584060
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Psychoeducational interventions to alleviate hot flashes: a systematic review.
    Tremblay A; Sheeran L; Aranda SK
    Menopause; 2008; 15(1):193-202. PubMed ID: 17589375
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Phase II study of vorozole (R83842), a new aromatase inhibitor, in postmenopausal women with advanced breast cancer in progression on tamoxifen.
    Goss PE; Clark RM; Ambus U; Weizel HA; Wadden NA; Crump M; Walde D; Tye LM; De Coster R; Bruynseels J
    Clin Cancer Res; 1995 Mar; 1(3):287-94. PubMed ID: 9815984
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Effect of shugan liangxue compound for relieving hot flashes in breast cancer patients].
    Sun H; Xue D; Gao F
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2009 Jan; 29(1):30-3. PubMed ID: 19338149
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women.
    Gibson LJ; Dawson C; Lawrence DH; Bliss JM
    Cochrane Database Syst Rev; 2007 Jan; (1):CD003370. PubMed ID: 17253488
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.